EU Panel Backs Conditional Approval for Liver Disease Drug Rezdiffra

Published on 06/20/2025 at 10:03

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Insider Sold Shares Worth $10,278,098, According to a Recent SEC Filing	Jul. 18	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $10,198,844, According to a Recent SEC Filing	Jul. 18	MT
Sector Update: Health Care Stocks Climb Late Afternoon	Jul. 16	MT
Sector Update: Health Care Stocks Gain in Afternoon Trading	Jul. 16	MT
Madrigal Pharmaceuticals Shares Rise Following US Patent Notice of Allowance for Rezdiffra	Jul. 16	MT
Sector Update: Health Care Stocks Rise Premarket Wednesday	Jul. 16	MT
Madrigal Pharmaceuticals Receives US Patent Notice of Allowance for Rezdiffra	Jul. 16	MT
Altimmune shares slump as weight-loss drug's fatty liver trial data disappoints	Jun. 26	RE
EU Panel Backs Conditional Approval for Liver Disease Drug Rezdiffra	Jun. 20	MT
Sector Update: Health Care Stocks Rise Premarket Friday	Jun. 20	MT
Exchange-Traded Funds Slightly Higher, Equity Futures Mixed Pre-Bell Friday as Geopolitical, Trade Risks Mount	Jun. 20	MT
EU regulator backs conditional authorisation for Madrigal's liver disease drug	Jun. 20	RE
Madrigal Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Resmetirom (Rezdiffra??) for the Treatment of Mash with Moderate to Advanced Liver Fibrosis	Jun. 20	CI
Madrigal Gets Positive Opinion From EMA for Resmetirom to Treat Liver Disease	Jun. 20	MT
EU medicines regulator backs conditional authorisation for Madrigal's liver disease drug	Jun. 20	RE
EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer'S Treatment	Jun. 20	RE
Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq listing rule	Jun. 17	RE
Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10:40 AM	Jun. 11
Madrigal Pharmaceuticals, Inc. - Special Call	Jun. 09
Aardvark Therapeutics, Inc. Announces Executive Changes	May. 19	CI
Madrigal Announces New Clinical Data Demonstrating Rezdiffra? Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated Mash Cirrhosis	May. 10	CI
Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis	May. 10	RE
UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating	May. 02	MT
Madrigal Pharmaceuticals Q1 Loss Narrows	May. 01	MT
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 01	CI